For the millions of Brazilians who lie awake in the dark, medicine has long offered a blunt instrument — chemicals that force the brain into unconsciousness, often at the cost of dependence and withdrawal. Brazil's health regulator Anvisa has now approved lemborexant, a drug that takes a quieter path: rather than compelling sleep, it silences the hormone that insists on wakefulness, allowing rest to arrive on its own terms. The approval, published in April, introduces a new class of sleep medicine to the country and reopens a question that has shadowed insomnia treatment for decades — whether
A Tribuna
· Sep 16, 2025
· health
· 2 min read
High
Sourcing: Verified
Anvisa approves lemborexant, new insomnia drug with lower dependence risk
◉
Health & Medicine
2792 related articles
Ozempic and GLP-1 drugs: how the weight-loss revolution works and what…
O GLOBO · 99% match
Anvisa aprova remdesivir contra covid-19 e registra vacina de Oxford
Jornal de Brasília · 90% match
Brazil Gets New Blood Test for Early Alzheimer's Detection
Olhar Digital · 90% match
Medical Expert Warns of Tirzepatide Risks, Emphasizes Need for Profess…
UNIPAR · 90% match
Berlin admits American Ebola patient as outbreak kills 131 in Congo
Folha de S.Paulo · 90% match
Related Coverage
O POVO · Aug 23
Dia D mobiliza Fortaleza com multivacinação e mutirão bucal em 264 locais
Fortaleza realizou mobilização massiva de imunização com 3 mil profissionais em 264 locais, incluindo multivacinação, mu…
Folha de S.Paulo · Aug 23 Tratar apneia do sono pode reduzir pressão arterial em hipertensosEstudo brasileiro demonstra que tratar apneia obstrutiva do sono contribui para reduzir hipertensão resistente, mesmo em…
Rádio Pampa · Aug 23 Duas em cada três pessoas com Alzheimer são mulheres; sintomas podem começar aos 45Pesquisa mostra que duas em cada três pessoas com Alzheimer são mulheres, com sintomas podendo começar aos 45 anos devid…
Rádio Pampa · Aug 23 Dieta rica em vegetais reduz risco de doença renal crônica, aponta estudoEstudo com 179.508 participantes mostra que dieta rica em vegetais, frutas e grãos integrais reduz risco de doença renal…
Bias & Framing
No detailed analysis data available for this lens. Try re-running lenses from the admin panel.
Geopolitical Impact
🌎
Brazil's approval of lemborexant represents a shift in pharmaceutical market access, with Japanese firm Eisai gaining regulatory entry in a major Latin American market for a safer insomnia treatment.
Escalation Risk
low
Confidence
MED
Brazil
Latin America
Japan
United States
Japanese pharmaceutical company Eisai expands market influence in Brazil's healthcare sector. This approval strengthens Japan's biotech soft power in Latin America and potentially reduces dependence on Western (US/European) drug manufacturers for Brazilian healthcare. Eisai's competitive advantage over incumbent sleep-aid producers (benzodiazepines, Z-drugs) may reshape regional pharmaceutical market share.
Similar to how Japanese automotive and electronics firms penetrated Latin American markets in the 1980s-90s, pharmaceutical companies are now establishing healthcare sector footholds through regulatory approvals of superior products.
Economic Lens
📈
Anvisa approved lemborexant (Dayvigo), a novel insomnia drug with lower dependency risk than existing treatments, potentially expanding Brazil's pharmaceutical market and improving patient outcomes in sleep disorder management.
Market Signal
bullish
Confidence
HIGH
Pharmaceutical manufacturing and distribution
Healthcare and medical services
Mental health and wellness
Insurance and healthcare financing
Consumers gain access to a safer insomnia treatment with reduced dependency risk compared to benzodiazepines and Z-drugs. However, affordability may be limited initially; at US pricing (~R$1,600/month), the drug targets higher-income patients until CMED pricing is established and potential insurance coverage is determined.
CMED must balance pricing to ensure market access while maintaining pharmaceutical innovation incentives. Potential for insurance coverage expansion and clinical guideline updates. Regulatory monitoring of long-term safety data (noted as inconclusive in studies) may be required. Possible substitution policies to reduce benzodiazepine dependency could follow.